Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-11-26
1998-11-10
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514340, 546276, 546277, A61K 31445, C07D41704
Patent
active
058344950
ABSTRACT:
The invention provides crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) L-hydrogentartrate, its preparation and use as a therapeutic agent.
REFERENCES:
patent: 5041455 (1991-08-01), Sauerberg
patent: 5043345 (1991-08-01), Sauerberg
patent: 5260311 (1993-11-01), Sauerberg
patent: 5264444 (1993-11-01), Sauerberg
Sauerberg et al., J. Med. Chem., vol. 35, pp. 2274-2283 (1992).
Berger et al "Pharmaceutical Salts" J. Pharm. Sci. 66(1) 1-19 (1977).
Hamilton et al., Journal of Chromatography, 613 (1993) pp. 365-270.
Levine et al., Life Science, vol. 52, Nos. 5/6 (1993).
Osborne Linda Marie
Petersen Torben G.
Shipley Lisa Ann
Treppendahl Svend
Chang Ceila
Lambiris Elias J.
Novo Nordisk A/S Novo Alle
Zelson Steve T.
LandOfFree
Crystalline xamoneline tartrate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline xamoneline tartrate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline xamoneline tartrate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1517167